Crescent Biopharma has dosed the first patient in ASCEND (NCT07335497), a global, open-label Phase 1/2 trial of CR-001, a tetravalent PD-1 x VEGF bispecific antibody, across multiple solid tumors. The study will enroll up to 290 patients in dose escalation, backfill, and dose-optimization cohorts in the United States, Europe, and Asia Pacific, spanning first-line and previously treated settings. Primary objectives are safety and tolerability; secondary measures include PK/PD, recommended Phase 2 dose, and preliminary antitumor activity (ORR, DoR, PFS, OS). Proof-of-concept data are targeted for the first quarter of 2027.
The core move is a bid to consolidate a clinically proven combination—PD-1 blockade plus VEGF inhibition—into a single biologic that Crescent intends to position as a backbone for its pipeline, including ADC combinations slated to start in the second half of 2026. ASCEND is the first of four planned trials in 2026, signaling an aggressive buildout designed to establish monotherapy and combination optionality early. The inclusion of both treatment-naïve and pretreated patients suggests Crescent is searching for the cleanest signal across several tumor types, with NSCLC and select gastrointestinal and gynecologic cancers as launch pads for indication prioritization.
Strategically, CR-001 enters a crowded field where PD-1 + anti-VEGF regimens are already embedded in standards of care and where at least one PD-1/VEGF bispecific has advanced with late-stage visibility. The bet is that a single-agent bispecific can harmonize exposure, streamline development and commercialization, and potentially widen the therapeutic window relative to co-administered antibodies and TKIs. That differentiation will have to show up either in tolerability, depth and durability of response, or operational simplicity that translates into cleaner Phase 3 execution. The 2027 proof-of-concept timeline underscores a measured path: Crescent appears intent on building a cross-indication dataset before declaring registrational intent, rather than rushing into a single Phase 2 bet.
For sites and CROs, the program is operationally attractive and demanding in equal measure. Broad, biomarker-agnostic eligibility should support steady accrual, but the dual mechanism will require cardio-oncology vigilance for hypertension, proteinuria, bleeding risk, and immune-related toxicities, with dose-optimization decisions hinging on AE management as much as early ORR. The PK/PD-heavy design points to tight sampling windows and central analytics, favoring networks with mature I/O infrastructure. Regulators will look for a disciplined narrowing to specific indications and lines of therapy; any registrational path will likely require randomized trials against entrenched PD-1–based combinations, not single-agent PD-1 comparators. For payers and hospital pharmacies, a consolidated product could reduce scheduling and infusion complexity, but that advantage is theoretical until pricing, dosing cadence, and real-world AE profiles are defined.
The next set of signals that matter: tolerability at active doses in dose escalation; any early response enrichment in NSCLC and VEGF-sensitive tumor contexts; and whether backfill cohorts sharpen the indication thesis quickly enough to design a clear Phase 2/3 path by late 2027. The ADC combination study will test Crescent’s backbone narrative, but it raises overlapping toxicity questions and adds trial complexity that could slow decision-making if monotherapy data are ambiguous. Coordination with Kelun-Biotech in Greater China could accelerate patient accrual and broaden the dataset, provided protocols and endpoints are harmonized to enable pooled analyses.
Bottom line: Crescent is playing a scale-and-synergy game—using a bispecific to anchor a multi-modality portfolio—against a high regulatory bar and entrenched competitors. Watch for whether ASCEND yields a convincingly differentiated safety-efficacy profile and a decisive indication choice. Without both, the path to a registrational program that can displace incumbent PD-1/VEGF strategies will be long.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
